Zentiva is involved in two court disputes according to Bloomberg. One of the cases challenges the sale of a land plot in Romania for more than CZK500m, while the other is a patent infringement claim submitted by Teva regarding Zentiva’s antihypertensive ATRAM (carvedilol). Our view: We see the news as neutral for the moment, although we see them as a potential risk factor. ATRAM does not belong to the top 10 drugs of Zentiva ranked by revenues generated.